These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34376583)

  • 21. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
    Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
    Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
    Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
    PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
    Suurs FV; Lorenczewski G; Stienen S; Friedrich M; de Vries EGE; de Groot DJA; Lub-de Hooge MN
    J Nucl Med; 2020 Nov; 61(11):1594-1601. PubMed ID: 32284393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microenvironment-responsive anti-PD-L1 × CD3 bispecific T-cell engager for solid tumor immunotherapy.
    Liu D; Bao L; Zhu H; Yue Y; Tian J; Gao X; Yin J
    J Control Release; 2023 Feb; 354():606-614. PubMed ID: 36669532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
    Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
    Brauchle B; Goldstein RL; Karbowski CM; Henn A; Li CM; Bücklein VL; Krupka C; Boyle MC; Koppikar P; Haubner S; Wahl J; Dahlhoff C; Raum T; Rardin MJ; Sastri C; Rock DA; von Bergwelt-Baildon M; Frank B; Metzeler KH; Case R; Friedrich M; Balazs M; Spiekermann K; Coxon A; Subklewe M; Arvedson T
    Mol Cancer Ther; 2020 Sep; 19(9):1875-1888. PubMed ID: 32518207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
    Wu Z; Guo HF; Xu H; Cheung NV
    Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
    Fisher TS; Hooper AT; Lucas J; Clark TH; Rohner AK; Peano B; Elliott MW; Tsaparikos K; Wang H; Golas J; Gavriil M; Haddish-Berhane N; Tchistiakova L; Gerber HP; Root AR; May C
    Cancer Immunol Immunother; 2018 Feb; 67(2):247-259. PubMed ID: 29067496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
    Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
    Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
    [No Abstract]   [Full Text] [Related]  

  • 31. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
    Osada T; Hsu D; Hammond S; Hobeika A; Devi G; Clay TM; Lyerly HK; Morse MA
    Br J Cancer; 2010 Jan; 102(1):124-33. PubMed ID: 19953093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors.
    Belmontes B; Sawant DV; Zhong W; Tan H; Kaul A; Aeffner F; O'Brien SA; Chun M; Noubade R; Eng J; Ma H; Muenz M; Li P; Alba BM; Thomas M; Cook K; Wang X; DeVoss J; Egen JG; Nolan-Stevaux O
    Sci Transl Med; 2021 Aug; 13(608):. PubMed ID: 34433637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.
    Panchal A; Seto P; Wall R; Hillier BJ; Zhu Y; Krakow J; Datt A; Pongo E; Bagheri A; Chen TT; Degenhardt JD; Culp PA; Dettling DE; Vinogradova MV; May C; DuBridge RB
    MAbs; 2020; 12(1):1792130. PubMed ID: 32684124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII.
    Sternjak A; Lee F; Thomas O; Balazs M; Wahl J; Lorenczewski G; Ullrich I; Muenz M; Rattel B; Bailis JM; Friedrich M
    Mol Cancer Ther; 2021 May; 20(5):925-933. PubMed ID: 33632870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
    Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
    Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
    Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
    AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.